Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review.
Dave Singh, Alvar Agusti, Fernando J Martinez...
https://pubmed.ncbi.nlm.nih.gov/35737975/Actively Recruiting
Led by Northumbria Healthcare NHS Foundation Trust · Updated on 2026-04-14
200
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating factors linked to low blood eosinophil counts eosinopenia in patients hospitalized with severe flare-ups of chronic obstructive pulmonary disease COPD. They aim to identify what influences eosinopenia on admission and to find out how long it takes for eosinophil levels to return to normal after such severe episodes. This observational study focuses on understanding these patterns to help guide treatment decisions, particularly regarding inhaled corticosteroids ICS. The study observes patients admitted with severe COPD exacerbations and measures their blood eosinophil counts over time. Participants are grouped based on whether their eosinophil counts are low or normal at admission. Blood samples and clinical data are collected at admission and repeatedly over six weeks to monitor recovery of eosinophil counts to a stable baseline. Researchers examine various clinical and physiological factors related to eosinopenia and its recovery. During the study, participants undergo blood tests, clinical assessments, and monitoring of their health status at admission, and at 1, 2, 3, 4, and 6 weeks afterward. The main outcomes include identifying factors associated with low eosinophil counts at admission and measuring the time needed for eosinophil levels to recover. Secondary analyses look at changes in immune markers, comparison with past exacerbations, and the influence of new exacerbations on eosinophil recovery. The total participation duration varies per participant but includes follow-up through six weeks post-admission.
CONDITIONS
Eosinopenia in Severe COPD Exacerbation
S
Stephen Bourke, MBChB, PhD
P
Peter Ireland, MBBS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Northumbria Healthcare NHS Foundation Trust
Lead Sponsor
Newcastle University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 weeks
Participants' blood eosinophil counts are measured at admission and during follow-up to assess recovery from eosinopenia and identify factors associated with eosinopenia during severe COPD exacerbation.
Visits at 1, 2, 3, 4, and 6 weeks from admission
Duration - Up to 6 weeks following admission
Participants are observed for changes in blood eosinophil counts and clinical status to understand recovery patterns and factors influencing eosinopenia after severe COPD exacerbation.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Dave Singh, Alvar Agusti, Fernando J Martinez...
https://pubmed.ncbi.nlm.nih.gov/35737975/David A Lipson, Frank Barnhart, Noushin Brealey...
https://pubmed.ncbi.nlm.nih.gov/29668352/Samy Suissa, Pierre Ernst
https://pubmed.ncbi.nlm.nih.gov/28797382/Mona Bafadhel, Stefan Peterson, Miguel A De Blas...
https://pubmed.ncbi.nlm.nih.gov/29331313/Carlos Echevarria, John Steer, Arun Prasad...
https://pubmed.ncbi.nlm.nih.gov/37487711/John Steer, John Gibson, Stephen C Bourke
https://pubmed.ncbi.nlm.nih.gov/22895999/David A Lipson, Courtney Crim, Gerard J Criner...
https://pubmed.ncbi.nlm.nih.gov/32162970/Northumbria Healthcare NHS Foundation Trust
Lead Sponsor
Newcastle University
Collaborating Sponsor